Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1366
Abstract: CPX‐351, a dual‐drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy‐related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia‐related changes.… read more here.
Keywords: cpx 351; exposure response; cytarabine daunorubicin;
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03856-9
Abstract: PurposeDaunorubicin can induce left ventricular dysfunction and QT interval prolongation. This study assessed the effects of CPX-351, a liposomal encapsulation of cytarabine and daunorubicin, on cardiac repolarization.MethodsTwenty-six adults with acute leukemia were treated with CPX-351… read more here.
Keywords: cpx 351; cardiac repolarization; phase study; cytarabine daunorubicin ... See more keywords
Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells
Sign Up to like & getrecommendations! Published in 2019 at "Drug Development and Industrial Pharmacy"
DOI: 10.1080/03639045.2018.1513026
Abstract: Abstract Purpose: CPX-351 is a liposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1 molar ratio, for the treatment of acute myeloid leukemia. The Scavenger Receptor class B type I (SR-BI) plays an important… read more here.
Keywords: k562; receptor class; uptake cpx; cpx 351 ... See more keywords
Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1744613
Abstract: Abstract Aims: Treatment of acute myeloid leukemia (AML) requires significant healthcare resource utilization (HRU), including lengthy hospitalizations. In a phase 3 study (NCT01696084), CPX-351 (Vyxeos) showed significant benefits to overall survival and complete remission versus… read more here.
Keywords: newly diagnosed; high risk; study; diagnosed high ... See more keywords
Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Orphan Drugs"
DOI: 10.1080/21678707.2016.1256768
Abstract: ABSTRACT Introduction: Despite uninterrupted efforts made to develop newer drugs and schedules in the treatment of acute myeloid leukemia (AML), the induction of chemotherapy with cytarabine and an anthracycline (the classical ‘7 + 3’) still… read more here.
Keywords: cytarabine daunorubicin; myeloid leukemia; cpx 351; treatment acute ... See more keywords
A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-119618
Abstract: Background: CPX-351 (Vyxeos®) is a liposomal nanoparticle of cytarabine and daunorubicin in a 5:1 molar ratio currently FDA approved for treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.… read more here.
Keywords: phase; study; level; cpx 351 ... See more keywords
Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124553
Abstract: Introduction: AML-MRC is an AML subtype that includes patients (pts) with (1) a history of myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm, (2) a MDS-related cytogenetic abnormality, or (3) multilineage dysplasia in >50% of ≥2 cell… read more here.
Keywords: research; consolidation; cpx 351; research funding ... See more keywords
Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136871
Abstract: Introduction: CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, has been approved by the US FDA and the EMA for the… read more here.
Keywords: research; cpx 351; research funding; twist ... See more keywords
Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-136880
Abstract: Introduction: CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, has been approved by the US FDA and EMA for the treatment… read more here.
Keywords: research; infusion; cpx 351; speakers bureau ... See more keywords
CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-137163
Abstract: CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of daunorubicin and cytarabine at a 1:5 synergistic ratio, is approved by the US FDA and EMA for the treatment of adults with… read more here.
Keywords: cpx 351; population; pediatric pts; cytarabine daunorubicin ... See more keywords
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003159
Abstract: CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). We retrospectively analyzed the efficacy and… read more here.
Keywords: high risk; real life; cpx 351; aml ... See more keywords